Seres therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on march 25, 2024, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to marella thorell, the company's new executive vice president and chief financial officer, consisting entirely of stock options. these stock options are.
MCRB Ratings Summary
MCRB Quant Ranking